BS_DV86M0Y7
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 12.693
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1ZVXF5FE | pilocytic astrocytoma | — | 0.919 |
| 2 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.904 |
| 3 | BS_Y7F9E2E9 | low-grade glioma | — | 0.898 |
| 4 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.897 |
| 5 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.892 |
| 6 | ERR2598332 | fetal | fetal | 0.892 |
| 7 | TCGA-J2-A4AE-01A-21R-A24H-07 | — | cohortA1 | 0.890 |
| 8 | s0099982 | — | — | 0.889 |
| 9 | MDT-AP-2047 | Med | Medulloblastoma | 0.887 |
| 10 | MDT-AP-0813 | Med | Medulloblastoma | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.332 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.316 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.219 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.216 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.171 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.155 | Inavolisib | — uncovered |
| COMPLEMENT | 0.154 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.141 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.141 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.127 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.125 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.102 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.095 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.092 | Inavolisib | — uncovered |
| COAGULATION | 0.087 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.085 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.068 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.049 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |